Abstract
Growing resistance of cancer cells to cytotoxic agents combined with dose-limiting toxicity continue to limit the full potential of chemotherapeutics in the clinical management of tumors. To respond to this impediment, researchers are increasingly turning to prospective adjuvant therapeutics for their ability to hypersensitize resistant malignant cells and, thereby, restore chemosensitivity. Among these adjuvants, nitric oxide has repeatedly been proved to serve as an effective hypersensitizing agent. Herein, we consider the applications of gene therapy versus nitric oxide donors for the delivery of chemosensitizing concentrations of nitric oxide.